The posting, in Summit Therapeutics's own words
archived Oct 13, 2026About Summit:
Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.
Overview of Role:
The Director, Clinical Operations Analytics & Performance Excellence leads the analytics strategy for the global clinical trial portfolio and serves as the business owner for operational performance analytics, metrics, portfolio reporting, Clinical Operations data governance, and Veeva Vault Clinical capabilities. This role functions as the Clinical Operations subject matter expert (SME) for the Veeva Vault Clinical platform, ensuring alignment between business processes, system capabilities, data standards, and operational reporting requirements. The Director translates operational data into actionable insights to improve study execution, portfolio predictability, resource planning, site performance, inspection readiness, and risk-based decision-making. This leader transforms operational data into strategic insights that improve study execution, portfolio predictability, resource planning, site performance, inspection readiness, and risk-based decision-making across the organization. Serving as the business lead and SME for Veeva Vault Clinical, the Director drives platform optimization, user adoption, process standardization, governance, and integration with the broader clinical technology ecosystem. Partnering with Clinical Operations, IT, Data Management, Biostatistics, RBM, Study Start-Up, Clinical Trial Management, and executive leadership, the Director develops scalable analytics capabilities and operational systems that enable data-driven study oversight and portfolio management. The role advances standardized data practices and leverages AI, automation, predictive analytics, and modern clinical technology platforms to support portfolio growth, operational excellence, and continuous process improvement.